• Guillermo Rosa-Diez, María Marina Papaginovic Leiva, Fernando Lombi, María Soledad Crucelegui, Ricardo D Martínez, Hernán Trimarchi, Rubén Schiavelli, Mercedes Grizzo, Miguel Raño, Ricardo M Heguilén, Rocío A Jones, Luciana González Paganti, Matías Ferrrari, Victoria Kjohede, Paula Zingoni, Jorge R Geffner, Daniel Ferrante, Fernán González Bernaldo De Quirós, and Vanina Pagotto.
• Servicio de Nefrología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. E-mail: guillermo.rosadiez@hospitalitaliano.org.ar.
• Medicina (B Aires). 2022 Jan 1; 82 (5): 631640631-640.

IntroductionGiven the vulnerability of chronic kidney disease individuals to SARS-CoV-2, nephrology societies have issued statements calling for prioritization of these patients for vaccination. It is not yet known whether COVID-19 vaccines grant the same high level of protection in patients with kidney disease compared to the non-dialysis population. The aims of this study were to evaluate the safety - measured by the adverse events potentially attributed to vaccines (ESAVI) - and the effectiveness - evaluated by the presence of antibodies - in dialysis patients immunized with the COVID-19 Sputnik V vaccine.Methodsmulticenter, observational and analytical study of a prospective cohort of hemodialysis patients from the Ciudad Autónoma de Buenos Aires participating in an official vaccination program. Dialysis requiring individuals older than 18 years, who received both components of the COVID-19 vaccine were included.ResultsData from 491 patients were included in the safety analysis. ESAVI with either the first or second component was detected in 186 (37.9%, 95% CI 33.6%-42.3%). Effectiveness analysis measuring antibodies levels against SARS-CoV-2 were performed in 102 patients; 98% presented these IgG antibodies at day 21 after the second component. In patients with COVID-19 prior to vaccination, antibodies at day 21 after the first component reached almost the highest levels compared to patients without previous COVID-19, but IgG rise among patients with previous COVID-19 was lower than in those without this previous disease.ConclusionThe Sputnik V vaccine has been shown to be safe and effective in this patient's population.

23 keywords...

hide…